StockNews.com Initiates Coverage on Senseonics (NYSE:SENS)

StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $2.00 target price on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Stock Up 3.1 %

Senseonics stock opened at $0.38 on Wednesday. The company has a current ratio of 3.11, a quick ratio of 2.89 and a debt-to-equity ratio of 59.17. Senseonics has a 1-year low of $0.37 and a 1-year high of $0.75. The firm’s fifty day simple moving average is $0.42 and its 200-day simple moving average is $0.48. The company has a market capitalization of $203.97 million, a P/E ratio of -2.74 and a beta of 0.82.

Senseonics (NYSE:SENS) last posted its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The company had revenue of $4.87 million for the quarter, compared to analyst estimates of $4.86 million. Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. Sell-side analysts forecast that Senseonics will post -0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Senseonics

A number of institutional investors have recently added to or reduced their stakes in SENS. Price T Rowe Associates Inc. MD lifted its position in shares of Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after acquiring an additional 51,000 shares during the period. RPO LLC acquired a new stake in Senseonics during the fourth quarter valued at approximately $37,000. Cubist Systematic Strategies LLC grew its stake in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after purchasing an additional 85,501 shares during the period. Vanguard Group Inc. raised its holdings in shares of Senseonics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after buying an additional 155,715 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System bought a new position in shares of Senseonics during the 1st quarter worth approximately $91,000. 12.36% of the stock is owned by institutional investors and hedge funds.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.